Judge pares down sales rep gender suit against Allergan's Forest unit; Teva tax incentives targeted in Israeli report;

@FiercePharma: U.S. government orders additional $133M of Bavarian Nordic's smallpox vaccine. FierceVaccines story | Follow @FiercePharma

@CarlyHFierce: Here's the latest episode of @FierceBiotech radio--and it even comes endorsed by @brentlsaunders! (He's real.) Listen | Follow @CarlyHFierce

> A federal judge narrowed a $100 million gender discrimination lawsuit against Allergan's ($AGN) Forest Laboratories unit, saying many of the claims from female sales reps may be time-barred. Report

> An Israeli government committee said Teva Pharmaceutical ($TEVA) enjoyed a third of the state's tax incentives from 2005 to 2010, while delivering just 1% of the nation's industrial jobs; the company pointed out that accounts for 1.5% of the country's GDP. Report

> Allergan's Actavis unit is recalling 26 lots of its Lutera contraceptive pills after learning they were distributed with outdated package inserts. Report

> The Finnish pharmaceutical company Orion hiked its 2015 profit forecast after stronger-than-expected performance in the first half. Report

> Teva Pharmaceutical rolled out its version of the migraine drug Axert (almotriptan malate), with exclusive generic rights through Nov. 7. Release | Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Study: Brain scan can be used to distinguish between traumatic brain injury and PTSD. Article | Follow @FierceMedDev

@EmilyWFierce: Sunshine Act payment data leaves out newly influential prescribers. More from FiercePharma | Follow @EmilyWFierce

> One year after IPO, Intersect ENT still going strong--starts pivotal testing, raises $103M. Story

> Not quite profitable, IPO star K2M cashes out investors with $177M in 2015. Report

Biotech News

@FierceBiotech: Who should make this year's Fierce 15? Nominate the most promising private biotechs. Nomination form | Follow @FierceBiotech

@JohnCFierce: Female libido drug lobbying sparks a backlash as FDA decision looms. Story | Follow @JohnCFierce

@DamianFierce: Patrick Soon-Shiong tacitly creates another company every time he does anything. NantKwest?! Press release | Follow @DamianFierce

> Back-to-back PhII flops for lead drug scuttles Aquinox stock. More

> J&J's IL-23 psoriasis contender scores a PhIIb win in a turbulent race. Article

> Celgene recommits to Epizyme, adding $620M in cancer drug bonuses. Report

Vaccines News

> Shantha's cholera jab prevents 37% of cholera cases in Bangladeshi study. More

> Poll: parents view vaccines as safer, more beneficial. Item

> J&J's HIV vaccine shows promise in monkeys; PhI/IIa to start soon. Article

> NIAID launches PhI trial of investigational West Nile virus vaccine. Story

> U.S. government orders additional $133M of Bavarian Nordic's smallpox vaccine. Report

CRO News

> Recipharm takes a 25% stake in its drug-developing partner. Item

> Parexel uses virtual clinical trials to improve real-life R&D. Report

> Charles River spends $212M to beef up its microbial testing. Story

> BioClinica buys a patient recruitment firm to bolster study startup. Article

Pharma Manufacturing News

> Twitter chat redux: In case you missed the chat, we don't want you to miss the info. More

> India may use FDA as model for bolstering its oversight. Item

> Lupin antibiotic products banned by Brazil. Story

> Chinese staffer key to negotiating deal to bolster FDA staff in China. Report

> FDA sends drugmakers warning letters reminding them to pay up. Article

Pharma Asia News

> India's Lupin hit by Brazil regulator suspension of antibiotic API. News

> Drug firms in Australia to report gifts to doctors starting Oct. 1, ABC says. Item

> India aims at U.S. FDA standards on drugs with name change afoot. Report

> Watch out AbbVie, Samsung Bioepis does fine with Humira biosimilar in PhIII. Story

> Israel's Oramed says $50M oral insulin deal with Sinopharm Capital-Hefei, not Guangxi Wuzhou. Article

And Finally... Three clusters of counties in the U.S. have "unnecessarily high" death rates from colon cancer. Report

Suggested Articles

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.

Sanofi has faced a probe into birth defects tied to seizure med Depakine for years. Now, the investigation is moving forward on manslaughter charges.

Pfizer launched a multichannel awareness campaign centered on a first-ever radio station dedicated solely to metastatic breast cancer.